Joris L. Vos - Concepedia

Author

Joris L. Vos

The Netherlands Cancer Institute ORCID

Also Known As

J. Vos, J.L. Vos, Joris L. Vos, Joris Vos, Vos, Joris L, Vos, Joris L.

Publications

878

Citations

H-Index

Concepts

All Affiliations

The Netherlands Cancer Institute Leiden University Medical Center Oncode Institute Memorial Sloan Kettering Cancer Center Maastricht University

About

Joris L. Vos is an author at The Netherlands Cancer Institute specializing in medicine, cancer therapeutics, and pharmacology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	110
2	Health Sciences	1	1	20
3	Head And Neck Surgery	1	1	20
4	Immunology	1	1	19
5	Orthopaedics	1	1	24

Joris L. Vos

Publications

862

Citations

H-Index

Page 1

	Year	Citations
Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma Joris L. Vos, Joris B.W. Elbers, Oscar Krijgsman, Nature Communications	2021	317
A pan-cancer analysis of the microbiome in metastatic cancer Thomas Battaglia, Iris Mimpen, Joleen J.H. Traets, Cell	2024	162
Prediction of checkpoint inhibitor immunotherapy efficacy for cancer using routine blood tests and clinical data Seong‐Keun Yoo, Conall Fitzgerald, Byuri Angela Cho, Nature Medicine	2025	79
Nivolumab plus ipilimumab in advanced salivary gland cancer: a phase 2 trial Joris L. Vos, Bharat Burman, Swati Jain, Nature Medicine OncologyMedicineImmune Checkpoint InhibitorCancer TreatmentPhase 2	2023	47
CD4+ T cells produce IFN-I to license cDC1s for induction of cytotoxic T-cell activity in human tumors Xin Lei, Daniël C. de Groot, Marij J.P. Welters, Cellular and Molecular Immunology	2024	46
Dual Immune Checkpoint Blockade Induces Analogous Alterations in the Dysfunctional CD8+ T-cell and Activated Treg Compartment Anne M. van der Leun, Joleen J.H. Traets, Joris L. Vos, Cancer Discovery	2023	32
[18F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma Joris L. Vos, Charlotte L. Zuur, Laura A. Smit, European Journal of Nuclear Medicine and Molecular Imaging	2021	31
Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma Cristina Valero, Mahdi Golkaram, Joris L. Vos, Journal of Clinical Investigation	2023	26
Bioactive glass obliteration of the mastoid significantly improves surgical outcome in non-cholesteatomatous chronic otitis media patients Joris L. Vos, Pieter de Vey Mestdagh, David R. Colnot, European Archives of Oto-Rhino-Laryngology Surgical OutcomeOtolaryngologyOtorhinolaryngologyBioactive Glass ObliterationSurgery	2017	24
Feasibility and toxicity of neoadjuvant nivolumab with or without ipilimumab prior to extensive (salvage) surgery in patients with advanced head and neck cancer (the IMCISION trial, NCT03003637). Charlotte L. Zuur, Joris B.W. Elbers, Joris L. Vos, Journal of Clinical Oncology Surgery W/wo RtRecurrent Metastatic HnsccSurgical OncologyNeck CancerNeoadjuvant Therapy	2019	20

Page 1